<DOC>
	<DOCNO>NCT01034085</DOCNO>
	<brief_summary>Background : - Some people schizophrenia problem work memory pay attention extend period . These difficulty treat antipsychotic medication many standard therapy . - The prevalence cigarette smoking among individual schizophrenia three time higher general population . Research show nicotine , addictive component find cigarette , help improve attentional work memory performance . Researchers interested learn whether may overlap cognitive function beneficially affect nicotine area dysfunction individual schizophrenia . Objectives : - To evaluate potential transdermal nicotine alleviate cognitive deficit schizophrenia , determine whether naturally maintain cigarette-smoking , comparison , effective self-medication . - To gather preliminary data genetics may account individual group difference performance effect nicotine . Eligibility : - Current smoker ( 25 cigarette per week least 1 year ) 18 55 year age either healthy volunteer diagnose schizophrenia/schizoaffective disorder . Design : - The study require five visit research center , initial screen visit , train session , three test session . Ideally , visit occur 1 week apart . - Training session : Participants receive train type computerize cognitive attentional behavior test give active portion study . Participants also fill questionnaire nicotine use alcohol drug use . - Test session : Participants assign random group complete test assess cognitive performance ( ) maintain usual smoking behavior , ( b ) minimal deprivation ( 3.5 hour without smoke ) wear placebo patch , ( c ) influence standard nicotine patch . The order session different individual participant . - Participants provide blood sample throughout research study evaluation purpose .</brief_summary>
	<brief_title>Effects Nicotine Areas Impaired Preserved Functioning Schizophrenia</brief_title>
	<detailed_description>Objective : 1 . To evaluate potential transdermal nicotine alleviate distinct cognitive deficit schizophrenia , determine whether naturally maintain cigarette-smoking , comparison , effective self-medication . 2 . To gather preliminary data genotype may account interindividual group difference performance effect nicotine . Study population : 45 regular smoker schizophrenia , 45 match control smoker ( great equal 5 cigarettes/day ) . Design : Double-blind , placebo-controlled , within-subject study , evaluate cognitive function condition normal smoking , transdermal nicotine ( 14 mg/day ) , placebo ( minimal tobacco deprivation ) . Outcome measure : Measures cognitive task performance , measure subjective state , plasma concentration nicotine metabolite , genotype regard gene cod nicotinic receptor subunit , MAO , COMT .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>INCLUSION CRITERIA : All participant : 1 . Age 18 55 . The aim minimize population inhomogeneity relate cognitive decline due normal age . 2 . Smoker 5 cigarette , cigarillo cigar per day , 5 days/week , least last 12 month 3 . Normal correct normal visual acuity ( least 20/100 ) . Participants mental illness , additional inclusion criterion : 1 . DSMIV diagnosis schizophrenia schizoaffective disorder 2 . Ability give write informed consent 3 . Four week stable pharmacological treatment ( psychiatric medication dose ) EXCLUSION CRITERIA : All participant : 1 . History myocardial infarction , heart failure , angina , stroke severe arrhythmia , EKG abnormality specify Screening method 2 . Uncontrolled high blood pressure ( rest systolic 150 diastolic 90 mm Hg ) 3 . Neurological condition stroke , seizure , dementia organic brain syndrome 4 . Any condition likely impair cognitive function mental retardation , attention deficit disorder severe pharmacological sedation 5 . Treatment tobacco dependence last four month 6 . Alcohol substance abuse dependence nicotine within last 12 month 7 . Pregnancy , verified urine pregnancy test female first visit begin two patch administration session 8 . Lactating Healthy control , additional exclusion criterion : 9 . Current psychiatric Axis I disorder Axis II schizophrenia spectrum disorder , verify Structured Clinical Interview DSMIV ( SCID ) Participants mental illness , additional exclusion criterion : 10 . Treated benztropine ( nicotinic muscarinic antagonist ) acetylcholine esterase inhibitor currently within last four week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 11, 2013</verification_date>
	<keyword>Nicotine</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Cognition</keyword>
	<keyword>Genes</keyword>
	<keyword>Smoking</keyword>
	<keyword>Cigarette Smoking</keyword>
</DOC>